Linda-Gail Bekker

Oct 28, 2024 | dailymaverick.co.za | Robin Wood |Linda-Gail Bekker

RETHINKING TB OP-ED Sputum-based diagnostics have held centre stage over the past century but recent detection of TB-causing bacteria in people’s breath challenges the current transmission paradigm. The tuberculosis notification rates in South Africa are as high today as they were reported in the early 1900s.

Oct 3, 2024 | theconversation.com | Gemma Ware |Linda-Gail Bekker

A new drug to prevent HIV infection is showing hugely promising results in clinical trials when injected every six months. In this episode of The Conversation Weekly podcast, we speak to South African HIV doctor and scientist Linda-Gail Bekker about her involvement in one of the trials for lenacapavir and why she thinks it could be so groundbreaking. Thanks to advancements in prevention and treatment, global HIV infection rates have dramatically declined in recent years.

Jul 14, 2024 | goodgoodgood.co | Linda-Gail Bekker

A large clinical trial in South Africa and Uganda has shown that a twice-yearly injection of a new pre-exposure prophylaxis drug gives young women total protection from HIV infection. The trial tested whether the six-month injection of lenacapavir would provide better protection against HIV infection than two other drugs, both daily pills. All three medications are pre-exposure prophylaxis (or PrEP) drugs.

Jul 13, 2024 | livescience.com | Linda-Gail Bekker

A large clinical trial in South Africa and Uganda has shown that a twice-yearly injection of a new pre-exposure prophylaxis drug gives young women total protection from HIV infection. The trial tested whether the six-month injection of lenacapavir would provide better protection against HIV infection than two other drugs, both daily pills. All three medications are pre-exposure prophylaxis (or PrEP) drugs.

Jul 12, 2024 | japantoday.com | Linda-Gail Bekker

A large clinical trial in South Africa and Uganda has shown that a twice-yearly injection of a new pre-exposure prophylaxis drug gives young women total protection from HIV infection. The trial tested whether the six-month injection of lenacapavir would provide better protection against HIV infection than two other drugs, both daily pills. All three medications are pre-exposure prophylaxis (or PrEP) drugs.